DONGSUNG PHARM. Co., Ltd. (002210) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 51 PAGES: 25

More Info
									               DONGSUNG PHARM. Co., Ltd. (002210) - Financial and Strategic
                                Analysis Review

      Reference Code: GDPH81902FSA                                                                                       Publication Date: AUG 2010

      703-14, Banghak-Dong,,                Phone                                                  Revenue
                                                             +82 2 34920921                                          68,724 (million KRW)
      Dobong-Gu
      Seoul                                 Fax              +82 2 34935132                        Net Profit         568.43 (million KRW)
      132-020                               Website          www.dongsung-pharm.co.kr              Employees          304
      Republic of Korea                     Exchange         002210 [Korea Stock Exchange] Industry                  Pharmaceuticals & Healthcare

      Company Overview
      DONGSUNG PHARM. Co., Ltd. (DONGSUNG) is a pharmaceutical company, engaged in the development, manufacturing and
      marketing of pharmaceutical products in multiple therapeutic areas. The product portfolio of DONGSUNG includes: respiratory
      system, digestive system, motion sickness and medicines including anti rheumatic and anti-inflammatory analgesics,
      gastrointestinal drugs, anti-inflammatory enzymes, cardiovascular system, antispasmodic agents, respiratory agents, anti-
      histamine, dermatologicals, antidiarheals, antibiotics, antifungals, oral hypoglycemic agents, hypotonics and sedatives and
      hormones. Additionally, DONGSUNG also provides hair dyes and related products.

      Key Executives                                                                 SWOT Analysis
                    Name                                   Title                     DONGSUNG PHARM. Co., Ltd., SWOT Analysis
      Lee Sun-Kyu                          Chairman                                  Strengths               Weaknesses

      Yang Gu Lee                          Chief Executive Officer
                                                                                     Robust Product Portfolio            Declining Profitability Ratios
      Jung Mu Gwon                         Director
      Yeon Su Kim                          Vice Chairman Management                  Strong Growth Prospects             Limited Liquidity Position
                                           Board
      Jeong Man Yim                        Director                                  Opportunities                       Threats
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                     Emerging Markets                    Counterfeit Drugs
      Share Data
                                                                                     Changing Demographic                Product Liability Claims
      DONGSUNG PHARM. Co., Ltd.
       Share Price (KRW) as on 25-Aug-2010                             1,760.0

       EPS (KRW)                                                         31.30
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research
       Market Cap (million KRW)                                         31,958       GlobalData

								
To top